Why did PHASQ stock fall so sharply on 17 Feb 2026?

PHASQ stock fell due to extremely low liquidity on PNK, legacy Chapter 11 restructuring concerns, and no offsetting positive news. Small trades moved price prints; volume was only 2,500.00 versus average 22,310.00.

What is Meyka AI’s grade for PHASQ stock and what it means?

Meyka AI rates PHASQ **62.73/100**, Grade B, Suggestion: HOLD. This score factors in benchmark and sector comparison, financials, key metrics, forecasts and analyst signals. Not financial advice.

What short-term trading risks should investors consider for PHASQ stock?

Short-term risks include quote volatility, wide bid-ask spreads, limited daily volume, and potential quote errors on PNK. Use tight risk controls and avoid leverage given the stock’s low liquidity.

Does Meyka AI forecast a recovery for PHASQ stock?

Meyka AI's model projects an indicative 12-month target of **$0.00010**, implying a large percentage upside from the current quote. Forecasts are model-based and not guarantees.

US Stocks

PHASQ stock plunges 99.00% to $0.000001 on PNK 17 Feb 2026: What traders should watch

ByHuzaifa Zahoor February 17, 2026February 17, 2026

PHASQ stock dropped -99.00% to $0.000001 on the PNK exchange during market hours on 17 Feb 2026, making it one of the session’s top losers. Volume was 2,500.00 shares versus a 50-day average of 22,310.00, signaling thin trading and extreme volatility for PhaseBio Pharmaceuticals, Inc. (PHASQ). The move follows continued Chapter 11 restructuring risk and limited liquidity in the United States OTC market. Traders should treat intraday quotes as highly unstable and weigh clinical and corporate news before positioning.